b-calkins-shutterstock-com
B Calkins / Shutterstock.com
16 December 2015Americas

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board (PTAB) not to institute an inter partes review (IPR) petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.

More on this story

Americas
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.

More on this story

Americas
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.